Pharmena S.A. with European Commission’s authorisation to market 1-MNA as a novel food ingredient
Pharmena S.A., a subsidiary of Pelion S.A., has received the European Commission’s authorisation for the marketing of 1-MNA as a novel food ingredient on the EU markets.
June 11th 2018 The Standing Committee on Plants, Animals, Food and Feed approved the draft Commission regulation authorising the placing on the market of 1-MNA as a novel food ingredient.
The European Commission’s decision opens up the way to marketing of this innovative dietary supplement, preventing atherosclerosis and cardiovascular diseases, in the EU. In the next step, the European Commission’s implementing regulation on the marketing of 1-MNA as a novel food ingredient under Regulation (EU) 2015/2283 of the European Parliament and of the Council of November 25th 2015 on novel foods must be published in the Official Journal of the European Union. The publication is to take place within a month.
Pharmena’s first dietary supplements based on 1-MNA are planned to be sold in Poland in the fourth quarter of 2018. In 2019, the company plans to launch sales in two other EU countries.
Pharmena will now be the only manufacturer of products containing 1-MNA in the world.
The 1-MNA dietary supplement will be an innovative product capable of influencing biomarkers of cardiovascular diseases and stimulating the endogenous (natural) synthesis of prostacyclin. Reduced level of prostacyclin in the body increases the risk of atherosclerosis. By raising the 1-MNA level, the supplement will stimulate secretion of prostacyclin, particularly in older people, thus reducing the risk of atherosclerosis.
Sources:
